🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are delighted to announce the appointment of Sarah Leroy who is taking the newly created position of Secretary General, responsible for managing Legal and Financial Affairs, Compliance, Human Resources, and ESG. She joins Jeito's executive committee. 👉 tinyurl.com/yc4uw9uk

Save the date! 📅Jeito will be at BioEquity Europe in San Sebastian from May 12-14. Rachel Mears and Ksenija Pavletic, Partners at Jeito Capital, will engage in two insightful roundtable discussions designed for innovative #biopharma companies. ⤵️ #privateequity

#AI opens a new era of therapeutic innovations. At the #FutureOfFinance Conference, I shared convictions on AI as a must have to accelerate therapeutic innovation for the benefit of patients. We can go faster for thousands of patients with high unmet needs!

We are thrilled to announce that our portfolio company HI-Bio: A Biogen Company has been acquired by Biogen Inc for up to $1.8 billion. This successful exit validates Jeito’s unique investment strategy focused on value-creation and patient benefit. 👉 jeito.life/en/jeito-capit…

18 months after Jeito’s initial investment, this exit is evidence of Jeito’s unique investment strategy of targeting pharma demand, selectively sourcing the best opportunities, and validating Jeito’s leading position within a syndicate of high-quality global investors. All proud!

💸 Cession à 1,8 milliard de dollars pour Jeito / La création de valeur au rendez-vous ➡wansquare.com/012-39567-Cess…

👏Congratulations to our portfolio company SparingVision for being selected once again in the #FT120 Index, highlighting the 120 most promising French companies with the potential to become global leaders in their markets. Proud to support your journey!

🗞️ Check out this article by BioCentury on Biogen's acquisition of HI-Bio: A Biogen Company from Jeito. Paul Bonanos highlights the exceptional quality of Hi-Bio's immunology and the significant value creation milestone achieved in the benefit of the patients👇biocentury.com/article/652489…

🚀 Second exit in a week! We are thrilled to announce the acquisition of Jeito’s portfolio company EyeBio by Merck for a potential value of $3 billion. This new exit validates further Jeito’s unique and differentiated investment model. Read more 👉 jeito.life/en/jeito-capit…

Through this new successful exit, Jeito demonstrates how its unique investment strategy and collective expertise bring value to the company, the patients and the investors. I wish the whole EyeBio team great success with Merck! #FasterFortThePatient #privateequity

Jeito Capital enchaîne les «success stories». La société d’investissement cède sa participation dans EyeBio à Merck dans le cadre d’une transaction pouvant atteindre les 3 milliards de dollars. #privateequity agefi.fr/private-equity…

📰 « Deux cessions majeures en une semaine » A lire dans Le Figaro le décryptage de la stratégie de Jeito qui a conduit aux cessions des deux entreprises de notre portefeuille : HI-Bio: A Biogen Company à Biogen et EyeBio à Merck. 👉 lefigaro.fr/societes/jeito…

🎙️ Rafaele Tordjman était sur BFM Business pour revenir sur les 2 cessions de Jeito cette semaine : Hi-Bio et EyeBio. Elles illustrent le succès de la stratégie de notre fonds et la forte demande pour des médicaments innovants pour des maladies sans solution thérapeutique ⤵️

The acquisition of HI-Bio by Biogen has been completed. Together, we will be advancing our clinical development plans to deliver innovative treatments to patients in need. Follow @Biogen for the latest news and read about the acquisition: investors.biogen.com/news-releases/…

"Privatizing Research to Share Innovation?": Don't miss this exceptional conference at #ReAix featuring Rafaele Tordjman, Founder and CEO of Jeito. Follow online the discussions, Saturday, July 6th at 5 PM 👉 lesrencontreseconomiques.fr/evenements/ses…

We are thrilled to share Jeito's participation in the $150 million Series D financing of #Catalym, our portfolio company developing novel immunotherapies to fight cancer. This new investment confirms CatalYm’s strong progress and potential. Read more 👉 jeito.life/en/jeito-capit…

Since our first investment in #CatalYm, we have been convinced that company was developing a promising new therapy approach to treat cancer. The recent and very impressive data reported by CatalYm makes us even more committed to renewing our support to its talented team. 👏

We would like to congratulate our co-founder José-Alain Sahel for being awarded the Wolf Prize for Medicine. The prize honors scientists and artists worldwide for their outstanding achievements in advancing science and the arts for the betterment of humanity. #WolfPrize

Join us at #VCF24 - starting tomorrow in Amsterdam ⏰ Our panel on Exit Strategies will ask ⤵️ 🔸 How do current market conditions impact exit strategies and LP expectations? 🔸 Can we anticipate a return of IPOs in Europe soon? 🔸 What strategies are LPs and GPs using to

Hier matin sur @RadioClassique, j’ai eu le plaisir de revenir sur le rôle et la mission de Jeito dans l'écosystème de l'innovation en santé. 2/3 des maladies connues aujourd'hui n'ont pas de traitement. Nous voulons accélérer pour les patients ! smartlink.ausha.co/le-focus-eco/r…